Dr. Manning explains the science of HAE, some challenges you may experience with HAE patients and a specific acute treatment therapy, RUCONEST.

Dr. Manning is a board-certified allergist and immunologist practicing in Arizona. Dr. Manning has been in practice since 1989 and sees 30 to 40 HAE patients every year. He has participated in more than 70 research projects and is the lead author or co-author on numerous allergy and immunology publications, including 8 about HAE.

The Science of HAE & the Importance of C1-INH

HAE presents a variety of treatment challenges.
In this video, we will explore and examine the existing and emerging science of HAE and the importance of C1 esterase inhibitor (C1-INH). The science of HAE is a culmination of more than 20 years of scientific research.
Clinical understanding of the underlying disease process is evolving, providing a greater knowledge base on which to build individualized treatment plans.

HAE Challenges

Practitioners treating HAE encounter a variety of challenges. In this video, we'll focus on two that you may see in your practice
- Redosing of acute treatment
- HAE with "normal" C1 esterase inhibitor (C1-INH)
  There have been no well-controlled prospective studies of C1-INH for the treatment of HAE in people with normal C1-INH lab results. The safety and efficacy of C1-INH replacement therapy in this patient population is unknown.

Delve into the science and HAE challenges

Cascade visualization of HAE

Abbreviation: HAE-nl-C1INH, HAE with normal C1 inhibitor.
Download the Cascade Visualization

Pharming partnered with a world authority on the pathogenesis and treatment of hereditary angioedema (HAE) to develop a visualization of the interconnectedness of the complement, contact activation, and fibrinolysis systems and how their interworkings lead to the symptomatology experienced in HAE attacks.

Use this visualization to explore the role of C1-INH in HAE attacks and potential HAE treatment challenges.

Redosing may prevent your patients from getting back to things that matter.

44% of patients experiencing HAE attacks have to retreat in order to get relief.

^*Based on literature, 3-44% of swells needed to be retreated

Let's take a look at a specific C1-INH, RUCONEST, for HAE challenges.

RUCONEST Efficacy and Safety

Science of HAE

Hear Dr. Michael Manning talk about the science of HAE and RUCONEST

Learn more

HAE challenges

Learn about two common challenges you may experience with HAE patients

Learn more

Why RUCONEST

See the efficacy and safety of RUCONEST

Learn more

Get Patients Started

Download a patient enrollment form here

Download Here

WHAT IS RUCONEST?

RUCONEST® (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

IMPORTANT SAFETY INFORMATION

RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment.

Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.

Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.

The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.

Before prescribing RUCONEST, please read the full Prescribing Information including the Patient Product Information.